A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
Trial Details
- NCT ID
- NCT07623798
- Phase
- PHASE3
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- Pomalidomide Capsules
- Bortezomib for Injection
- Daratumumab Injection (Subcutaneous Injection)
- IBI3003
- Selinexor Tablets
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Age ≥18 years.
- Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.
- At least one of the following measurable disease indicators:
- Serum M-protein ≥ 5 g/L(For IgA and IgD subtypes, it is recommended to use quantitative immunoglobulin measurements instead of M protein)
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →